Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM and DecImmune Therapeutics Sign Agreement

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Agreement to develop N2 pathway blocking antibody.

DSM Pharmaceutical Products has announced that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

The agreement covers the initiation of development activities by DSM for DecImmune's lead monoclonal antibody program.

The initial development will be performed at DSM Biologics' Groningen, the Netherlands, facility, with the objective of progressing manufacture of clinical trial material to DSM's facility in Brisbane, Australia.

DecImmune's proprietary antibody therapeutic is designed to reduce tissue damage and improve ventricular function associated with myocardial infarction.

Regaining full function after a heart attack can be complicated by irreversible tissue damage and scar formation that leads to a significant loss in cardiac pumping efficiency.

In a range of experimental models, DecImmune has shown that it is possible to reduce damage to heart tissue by using their proprietary therapeutic antibody.

In these models the reduction in damage to heart tissue results in pumping efficiency returning to normal levels. DecImmune is also investigating this targeted approach to reduce tissue damage for a range of other acute and chronic post-injury settings.

Karen King, President of DSM Biologics, commented “We are delighted to be working with DecImmune on their exciting project. DSM is committed to delivering our clients around the world the highest quality solutions and services.”

DSM Biologics, a business unit of DSM Pharmaceutical Products, focuses on optimizing mammalian-based biopharmaceutical manufacturing through its unique set of technologies and expertise.

In addition to an R&D and manufacturing site in Groningen, the Netherlands, DSM is starting up operations in 2013 in Brisbane, Australia, with the support of the Government of Queensland and the Commonwealth of Australia.

The Brisbane facility is DSM's prototype 'biologics plant of the future' for the production of biopharmaceuticals employing DSM's proprietary technologies.

DSM's technologies drive down cost, processing times, scale-up risk and capital requirements to meet market demand for developing cost-effective, lifesaving medications.

"Partnering with DSM for its antibody process development and manufacturing enables DecImmune to move rapidly through late preclinical studies and into clinical development. DSM's experience, capacity, and technical expertise in Groningen and Brisbane meet the full range of DecImmune's manufacturing needs. We look forward to working with one of the world's leading science-based companies as our manufacturing partner," stated Christopher K. Mirabelli, Ph.D., President and CEO of DecImmune and Managing Director at HealthCare Ventures, DecImmune's lead investor.

"In line with DSM's stated strategy, and fulfillment of its commitment to bring manufacturing and technological excellence to the global biopharmaceutical market, this agreement with DecImmune represents the best of what DSM is doing to help our customers serve critical needs in healthcare. The combination of the Groningen and Brisbane operations will support DecImmune throughout the development process and on to clinical trials." declared Alexander Wessels, President and CEO of DSM Pharmaceutical Products.

David Hughes, CEO of BioPharmaceuticals Australia (BPA), said "We have always been of the view that success for this facility would come from leveraging both local and global demand. BPA’s ongoing partnership with DSM brings a wealth of expertise to the region. Brisbane is home to sophisticated biomanufacturing technology and this contract with DecImmune bolsters the city as an internationally-recognized location for biotherapeutic development."

BPA, an industry-development company owned by the Queensland State Government, put together the partnering deal with DSM Biologics, and is currently project managing the final stages of the construction of the new facility in cooperation with DSM Biologics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM and Opthea Sign Agreement
Agreement to manufacture Opthea’s lead product for eye disease.
Wednesday, October 30, 2013
DSM Celebrates Opening of New cGMP Facility
DSM Pharmaceutical Products officially opens its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.
Wednesday, October 30, 2013
DSM Announces Biologics Development and Manufacturing Agreement for Australian Facility
DSM has signed a biologics contract manufacturing agreement with Paranta Biosciences.
Thursday, October 25, 2012
DSM Announces South American Biologics Contract Manufacturing Agreement
DSM sign contract manufacturing agreement with RECEPTA Biopharma.
Tuesday, July 17, 2012
PolyTherics Moves Lead Candidate into Development and Manufacturing with DSM BioSolutions
Both the companies have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG™ IFN a-2a.
Friday, September 10, 2010
DSM Publishes DNA Genome Sequence of Penicillin Producer Penicillium Chrysogenum
Royal DSM has announced the publication of a paper on a breakthrough analysis of the DNA sequence of the fungus Penicillium chrysogenum.
Wednesday, October 01, 2008
DSM Invests EUR 2 Million in Finnish Genetic Discovery Company
Following investments in Sciona and Integragen, this is DSM’s third equity investment in Personalized Nutrition.
Thursday, September 06, 2007
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!